Telomere Gene Therapy: Polarizing Therapeutic Goals for Treatment of Various Diseases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, JinWoo | - |
dc.contributor.author | Yun, Chae-Ok | - |
dc.date.accessioned | 2021-07-30T05:23:08Z | - |
dc.date.available | 2021-07-30T05:23:08Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2019-05 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4582 | - |
dc.description.abstract | Modulation of telomerase maintenance by gene therapy must meet two polarizing requirements to achieve different therapeutic outcomes: Anti-aging/regenerative applications require upregulation, while anticancer applications necessitate suppression of various genes integral to telomere maintenance (e.g., telomerase, telomerase RNA components, and shelterin complex). Patients suffering from aging-associated illnesses often exhibit telomere attrition, which promotes chromosomal instability and cellular senescence, thus requiring the transfer of telomere maintenance-related genes to improve patient outcomes. However, reactivation and overexpression of telomerase are observed in 85% of cancer patients; this process is integral to cancer immortality. Thus, telomere-associated genes in the scope of cancer gene therapy must be inactivated or inhibited to induce anticancer effects. These contradicting requirements for achieving different therapeutic outcomes mean that any vector-mediated upregulation of telomere-associated genes must be accompanied by rigorous evaluation of potential oncogenesis. Thus, this review aims to discuss how telomere-associated genes are being targeted or utilized in various gene therapy applications and provides some insight into currently available safety hazard assessments. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.title | Telomere Gene Therapy: Polarizing Therapeutic Goals for Treatment of Various Diseases | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yun, Chae-Ok | - |
dc.identifier.doi | 10.3390/cells8050392 | - |
dc.identifier.wosid | 000470994400012 | - |
dc.identifier.bibliographicCitation | CELLS, v.8, no.5, pp.1 - 17 | - |
dc.relation.isPartOf | CELLS | - |
dc.citation.title | CELLS | - |
dc.citation.volume | 8 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 17 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | REVERSE-TRANSCRIPTASE PROMOTER | - |
dc.subject.keywordPlus | NUCLEUS PULPOSUS CELLS | - |
dc.subject.keywordPlus | HUMAN CANCER-CELLS | - |
dc.subject.keywordPlus | CARDIOVASCULAR-DISEASE | - |
dc.subject.keywordPlus | ONCOLYTIC ADENOVIRUS | - |
dc.subject.keywordPlus | MEDIATED INHIBITION | - |
dc.subject.keywordPlus | PULMONARY-FIBROSIS | - |
dc.subject.keywordPlus | RNA INTERFERENCE | - |
dc.subject.keywordPlus | LIVER-CIRRHOSIS | - |
dc.subject.keywordPlus | HTERT PROMOTER | - |
dc.subject.keywordAuthor | telomere | - |
dc.subject.keywordAuthor | telomerase | - |
dc.subject.keywordAuthor | telomere dysfunction | - |
dc.subject.keywordAuthor | gene therapy | - |
dc.subject.keywordAuthor | anti-aging | - |
dc.subject.keywordAuthor | regenerative medicine | - |
dc.subject.keywordAuthor | cancer therapy | - |
dc.identifier.url | https://www.mdpi.com/2073-4409/8/5/392 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.